Safety and Efficacy of 4‐Aminopyridine in Humans with Spinal Cord Injury: A Long‐Term, Controlled Trial
Authors:
- 1 June 1999
- journal article
- clinical trial
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 19 (6) , 713-723
Abstract
Study Objective. To determine the effects of the long‐term administration of 4‐aminopyridine (4‐AP) on sensorimotor function in humans with longstanding spinal cord injury (SCI).Design. Randomized, open‐label, active‐treatment control, dosage‐blinded study.Setting. University‐affiliated, tertiary‐level care, Department of Veterans Affairs Medical Center.Patients. Twenty‐one healthy men and women outpatients suffering from traumatic SCI (14 tetraplegic, 7 paraplegic) for 2 years or more.Interventions. Dosages of an immediate‐release formulation of 4‐AP were titrated. At 3 months, 16 subjects were receiving 4‐AP 30 mg/day (high dose); 5 subjects were receiving 4‐AP 6 mg/day (low dose) and served as an active‐treatment control group.Measurements and Main Results. Composite motor and sensory scores had statistically significant increases at 3 months. Maximal expiratory pressure, maximal inspiratory pressure, forced vital capacity, and forced expiratory volume in 1 second showed clinically meaningful and/or statistically significant increases among patients receiving 4‐AP 30 mg/day. These subjects also had significant decreases in spasticity (modified Ashworth Scale). Serial biochemical profiles and electroencephalographs were unchanged from baseline, and no clinically significant drug toxicity was encountered.Conclusions. Long‐term oral administration of immediate‐release 4‐AP was associated with improvement in and recovery of sensory and motor function, enhanced pulmonary function, and diminished spasticity in patients with long‐standing SCI. 4‐Aminopyridine appears to be safe and relatively free from toxicity when administered orally over 3 months. Each patient who received immediate‐release 4‐AP 30 mg/day showed a response in one or more of the outcome measures.Keywords
This publication has 25 references indexed in Scilit:
- Randomized Double-Blind Crossover Trial of Fampridine-SR (Sustained Release 4-Aminopyridine) in Patients With Incomplete Spinal Cord InjuryJournal of Neurotrauma, 1998
- VENTILATORY FUNCTION IN CERVICAL AND HIGH THORACIC SPINAL CORD INJURYAmerican Journal of Physical Medicine & Rehabilitation, 1997
- Pharmacokinetic Considerations in Rational Drug DesignClinical Pharmacokinetics, 1994
- 4-Aminopyridine in Patients with Multiple SclerosisClinical Neuropharmacology, 1993
- 4-Aminopyridine in Chronic Spinal Cord Injury: A Controlled, Double-Blind, Crossover Study in Eight PatientsJournal of Neurotrauma, 1993
- Repeated measurements of pulmonary function following spinal cord injurySpinal Cord, 1992
- Decreased Systemic Clearance of Lorazepam in Humans With Spinal Cord InjuryThe Journal of Clinical Pharmacology, 1991
- The Effects of 4-Aminopyridine on Neurological Deficits in Chronic Cases of Traumatic Spinal Cord Injury in Dogs: A Phase I Clinical TrialJournal of Neurotrauma, 1991
- Effects of 4-aminopyridine on synaptic transmission in the cat spinal cordBrain Research, 1982
- Diverse sensory functions with an almost totally divided spinal cord. A case of spinal cord transection with preservation of part of one anterolateral quadrantPain, 1976